Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups
Authors
Keywords
-
Journal
CTS-Clinical and Translational Science
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-09-17
DOI
10.1111/cts.12585
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Avibactam Pharmacokinetic/Pharmacodynamic Targets
- (2018) Wright W. Nichols et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Experimental design and modelling approach to evaluate efficacy of β-lactam/β-lactamase inhibitor combinations
- (2018) S.K.B. Sy et al. CLINICAL MICROBIOLOGY AND INFECTION
- A mathematical model-based analysis of the time–kill kinetics of ceftazidime/avibactam against Pseudomonas aeruginosa
- (2018) Sherwin K B Sy et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
- (2018) Antoni Torres et al. LANCET INFECTIOUS DISEASES
- A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia
- (2017) Xinyu Qin et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Global Dissemination ofblaKPCinto Bacterial Species beyond Klebsiella pneumoniae andIn VitroSusceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam
- (2016) Krystyna M. Kazmierczak et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroSusceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014)
- (2016) Wright W. Nichols et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroSusceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014)
- (2016) Boudewijn L. M. de Jonge et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
- (2016) Florian M. Wagenlehner et al. CLINICAL INFECTIOUS DISEASES
- Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
- (2016) John E. Mazuski et al. CLINICAL INFECTIOUS DISEASES
- Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
- (2016) Yehuda Carmeli et al. LANCET INFECTIOUS DISEASES
- Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection
- (2015) Johanna Berkhout et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents
- (2015) Eduardo Asín-Prieto et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model
- (2014) Ken Coleman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions
- (2014) Jason A Roberts et al. LANCET INFECTIOUS DISEASES
- Structural Insight into Potent Broad-Spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-Lactamases
- (2013) Sushmita D. Lahiri et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Contemporary Diversity of β-Lactamases among Enterobacteriaceae in the Nine U.S. Census Regions and Ceftazidime-Avibactam Activity Tested against Isolates Producing the Most Prevalent β-Lactamase Groups
- (2013) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Pharmacodynamics of Antipseudomonal Cephalosporins in Patients with Ventilator-Associated Pneumonia
- (2013) Shawn H. MacVane et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Organisms Collected from U.S. Medical Centers in 2012
- (2013) Helio S. Sader et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Urinary Tract Infection
- (2013) Lindsay E. Nicolle CRITICAL CARE CLINICS
- Hospital-acquired pneumonia and ventilator-associated pneumonia
- (2013) François Barbier et al. CURRENT OPINION IN PULMONARY MEDICINE
- Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
- (2013) George G. Zhanel et al. DRUGS
- Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial
- (2013) Christopher Lucasti et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value
- (2013) Robert K. Flamm et al. JOURNAL OF CHEMOTHERAPY
- Complicated intra-abdominal infections in a worldwide context: an observational prospective study (CIAOW Study)
- (2013) Massimo Sartelli et al. World Journal of Emergency Surgery
- In VitroAntibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical Isolates
- (2012) Premavathy Levasseur et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study
- (2012) José A. Vazquez et al. CURRENT MEDICAL RESEARCH AND OPINION
- Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia
- (2012) A. E. Muller et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ready for a world without antibiotics? The Pensières Antibiotic Resistance Call to Action
- (2012) Jean Carlet et al. Antimicrobial Resistance and Infection Control
- The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach
- (2011) J.W. Mouton et al. CLINICAL MICROBIOLOGY AND INFECTION
- In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae
- (2011) Z. Aktaş et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Rational dosing of antimicrobial agents: Pharmacokinetic and pharmacodynamic strategies
- (2009) R. C. Owens et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Augmented Renal Clearance
- (2009) Andrew A. Udy et al. CLINICAL PHARMACOKINETICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation